[Correspondence] WHO recommendations for multidrug-resistant tuberculosis – Authors’ reply
We agree entirely with Catherine Berry and colleagues that improving patient outcomes is a major objective we all share. Unfortunately, a large majority who are representative of patients treated in our centres1,2would not benefit from the shorter multidrug-resistant (MDR) tuberculosis regimen: only 14 (4·0%) of 348 patients would benefit. This is most likely because we have had a backlog of very resistant patients to treat. We hypothesise that when these patients are treated, more patients will be able to benefit from the shorter regimen.